STROBE Statement—Checklist of items that should be included in reports of *cross-sectional studies* 

2 3 4 5	Recommendation  (a) Indicate the study's design with a commonly used term in the title or the abstract  (b) Provide in the abstract an informative and balanced summary of what was done and what was found  Explain the scientific background and rationale for the investigation being reported  State specific objectives, including any prespecified hypotheses  Present key elements of study design early in the paper  Describe the setting, locations, and relevant dates, including periods	1 2-3 4 5 5-7 5
3 4 5	or the abstract  (b) Provide in the abstract an informative and balanced summary of what was done and what was found  Explain the scientific background and rationale for the investigation being reported  State specific objectives, including any prespecified hypotheses  Present key elements of study design early in the paper  Describe the setting, locations, and relevant dates, including periods	5 5-7
3 4 5	what was done and what was found  Explain the scientific background and rationale for the investigation being reported  State specific objectives, including any prespecified hypotheses  Present key elements of study design early in the paper  Describe the setting, locations, and relevant dates, including periods	5 5-7
3 4 5	Explain the scientific background and rationale for the investigation being reported  State specific objectives, including any prespecified hypotheses  Present key elements of study design early in the paper  Describe the setting, locations, and relevant dates, including periods	5 5-7
3 4 5	State specific objectives, including any prespecified hypotheses  Present key elements of study design early in the paper  Describe the setting, locations, and relevant dates, including periods	5 5-7
3 4 5	State specific objectives, including any prespecified hypotheses  Present key elements of study design early in the paper  Describe the setting, locations, and relevant dates, including periods	5 5-7
4 5	State specific objectives, including any prespecified hypotheses  Present key elements of study design early in the paper  Describe the setting, locations, and relevant dates, including periods	5-7
4 5	Present key elements of study design early in the paper  Describe the setting, locations, and relevant dates, including periods	5-7
5	Describe the setting, locations, and relevant dates, including periods	
5	Describe the setting, locations, and relevant dates, including periods	
		5
6	. C	
6	of recruitment, exposure, follow-up, and data collection	
0	(a) Cohort study—Give the eligibility criteria, and the sources and	5
	methods of selection of participants. Describe methods of follow-up	(Cross-
	Case-control study—Give the eligibility criteria, and the sources and	sectional
	methods of case ascertainment and control selection. Give the	study)
	rationale for the choice of cases and controls	27
		N/A
		1,112
7	•	5-7
8*	**	5-7
	-	
9		N/A
10		N/A
11	· · · · · · · · · · · · · · · · · · ·	5-6
	·	
12		7
		N/A
		N/A
		N/A
	•	11/11
		N/A
	<u> </u>	- W
13*	(a) Report numbers of individuals at each stage of study—eg numbers	N/A
1.5		11/11
	9 10 11	of recruitment, exposure, follow-up, and data collection  (a) Cohort study—Give the eligibility criteria, and the sources and methods of selection of participants. Describe methods of follow-up Case-control study—Give the eligibility criteria, and the sources and methods of case ascertainment and control selection. Give the rationale for the choice of cases and controls  Cross-sectional study—Give the eligibility criteria, and the sources and methods of selection of participants  (b) Cohort study—For matched studies, give matching criteria and number of exposed and unexposed  Case-control study—For matched studies, give matching criteria and the number of controls per case  Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers. Give diagnostic criteria, if applicable  For each variable of interest, give sources of data and details of methods of assessment (measurement). Describe comparability of assessment methods if there is more than one group  Describe any efforts to address potential sources of bias  Explain how the study size was arrived at  Explain how quantitative variables were handled in the analyses. If applicable, describe which groupings were chosen and why  (a) Describe all statistical methods, including those used to control for confounding  (b) Describe any methods used to examine subgroups and interactions  (c) Explain how missing data were addressed  (d) If applicable, describe analytical methods taking account of sampling strategy  (g) Describe any sensitivity analyses

		(b) Give reasons for non-participation at each stage	N/A
		(c) Consider use of a flow diagram	N/A
Descriptive data	14*	(a) Give characteristics of study participants (eg demographic,	7-10,20-22
		clinical, social) and information on exposures and potential	
		confounders	
		(b) Indicate number of participants with missing data for each	N/A
		variable of interest	
Outcome data	15*	Cohort study—Report numbers of outcome events or summary	N/A
		measures over time	
		Case-control study—Report numbers in each exposure category, or	N/A
		summary measures of exposure	
		Cross-sectional study—Report numbers of outcome events or	7-8
		summary measures	
Main results	16	(a) Give unadjusted estimates and, if applicable, confounder-adjusted	7-10
		estimates and their precision (eg, 95% confidence interval). Make	
		clear which confounders were adjusted for and why they were	
		included	
		(b) Report category boundaries when continuous variables were	N/A
		categorized	
		(c) If relevant, consider translating estimates of relative risk into	N/A
		absolute risk for a meaningful time period	
Other analyses	17	Report other analyses done—eg analyses of subgroups and	N/A
		interactions, and sensitivity analyses	
Discussion			
Key results	18	Summarise key results with reference to study objectives	13
Limitations	19	Discuss limitations of the study, taking into account sources of	13
		potential bias or imprecision. Discuss both direction and magnitude	
		of any potential bias	
Interpretation	20	Give a cautious overall interpretation of results considering	10-13
		objectives, limitations, multiplicity of analyses, results from similar	
		studies, and other relevant evidence	
Generalisability	21	Discuss the generalisability (external validity) of the study results	13
Other information			
Funding	22	Give the source of funding and the role of the funders for the present	1
		study and, if applicable, for the original study on which the present	
		article is based	

<sup>\*</sup>Give information separately for exposed and unexposed groups.

**Note:** An Explanation and Elaboration article discusses each checklist item and gives methodological background and published examples of transparent reporting. The STROBE checklist is best used in conjunction with this article (freely available on the Web sites of PLoS Medicine at http://www.plosmedicine.org/, Annals of Internal Medicine at http://www.annals.org/, and Epidemiology at http://www.epidem.com/). Information on the STROBE Initiative is available at www.strobe-statement.org.